Hostname: page-component-586b7cd67f-rcrh6 Total loading time: 0 Render date: 2024-11-28T20:02:23.892Z Has data issue: false hasContentIssue false
  • English
  • Français

Baclofen in cannabis dependence syndrome - a open-label study and a brief follow up

Published online by Cambridge University Press:  16 April 2020

N. Subodh ,
P. Chand ,
P. Murthy ,
S. Madhusudhan  and
V. Benegal
N. Subodh
Affiliation:
Psychiatry, Bangalore, India
P. Chand
Affiliation:
Psychiatry, Bangalore, India
P. Murthy
Affiliation:
NIMHANS, Bangalore, India
S. Madhusudhan
Affiliation:
NIMHANS, Bangalore, India
V. Benegal
Affiliation:
NIMHANS, Bangalore, India

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Aim

To study the effect of baclofen in preventing drug use in persons with cannabis misuse.

Methodology

An open label study to asses the effect of baclofen in treating persons with cannabis dependence (ICD-10 criteria) with assessments of outcome every month for a period of three months.

Results

20 male subjects (mean age of 29.70 ± 10.19 years) with a mean age at development of dependence of 20.75 ± 09.34 years and mean duration of cannabis use of 89.40 ± 57.41 months, were treated with baclofen (mean dose of 33.75 ± 04.83 mg./day). At three months 12 subjects (60%) completely stopped, 6 subjects (30%) decreased the frequency and 2 subjects (10%) continued the same frequency of the cannabis intake.

Conclusion

Our findings provide preliminary support for the use of baclofen in maintaining abstinence and improving outcome in patients with cannabis dependence.

Type
P01-110
Information
European Psychiatry , Volume 26 , Issue S2: Abstracts of the 19th European Congress of Psychiatry , March 2011 , pp. 110
Copyright
Copyright © European Psychiatric Association 2011
Submit a response

Comments

No Comments have been published for this article.